Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1021 articles with Allergan, Inc.
-
CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For Summer
3/21/2019
CoolSculpting, owned by Allergan plc, is partnering once again with television personality on Bravo's "The Real Housewives of New York City", philanthropist and fashion lifestyle entrepreneur Sonja Morgan to help women prepare for warmer weather and banish their Bikini Denial this summer.
-
CoolSculpting® and Sonja Morgan Partner to Talk Bikini Denial
3/20/2019
Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment*
-
Allergan, which has been a leader in the migraine space, hopes to have a new treatment available for patients using a new mechanism of action for acute treatment of migraine.
-
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
3/18/2019
Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older
-
Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting
3/14/2019
New data to address the treatment duration potential of first-in-class sustained release biodegradable implant
-
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
3/11/2019
Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine
-
After Allergan reported that its late-stage adjunctive treatment for major depressive disorder failed to distinguish itself against placebo, hedge fund investor Appaloosa LP is again calling on the Ireland-based company to make some changes to its board of directors, including tapping a new chair...
-
Appaloosa Issues Statement Regarding Allergan’s Failed Anti-Depression Study
3/7/2019
Latest Sign Allergan’s Open Science Model Is Broken; Reiterates Call for Independent Chairman
-
The company said rapastinel will not likely hit primary and secondary endpoints in three acute studies based on data from an interim analysis.
-
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)
3/6/2019
Interim analysis of relapse prevention study suggests the primary endpoint will not be met
-
Allergan to Present at The Cowen and Company 39th Annual Health Care Conference
3/4/2019
Allergan plc announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.
-
Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.
3/1/2019
Allergan plc announced that its data will be featured during the 2019 American Academy of Dermatology Annual Meeting in Washington D.C. March 1-5, 2019.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
Robert J. Hugin Appointed to Allergan Board of Directors
2/19/2019
Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company
-
Allergan Responds to Public Shareholder Letter - February 19, 2019
2/19/2019
Allergan plc today issued the following statement from its Board of Directors in response to a public shareholder letter.
-
Allergan to Present at The 8th Annual SVB Leerink Global Healthcare Conference
2/15/2019
Allergan plc, a leading global biopharmaceutical company, announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY.
-
According to a real estate analysis, the per-square-foot costs in Kendall Square increased $18 in 2018.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allergan plc. of Class Action Lawsuit and Upcoming Deadline - AGN
1/30/2019
Pomerantz LLP announces that a class action lawsuit has been filed against Allergan plc. and certain of its officers.
-
Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results
1/29/2019
Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion
-
New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand
1/28/2019
Campaign targets new generation of users with an updated, modern approach